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advice for women who are overweight or
obese on neonatal health outcomes: the LIMIT
randomised trial
Jodie M Dodd1,2*, Andrew J McPhee3, Deborah Turnbull4, Lisa N Yelland1,5,6, Andrea R Deussen1,
Rosalie M Grivell1,2, Caroline A Crowther1,8, Gary Wittert7, Julie A Owens1, Jeffrey S Robinson1
and For the LIMIT Randomised Trial GroupAbstract
Background: Overweight and obesity during pregnancy represents a considerable health burden. While research
has focused on interventions to limit gestational weight gain, there is little information describing their impact on
neonatal health. Our aim was to investigate the effect on a range of pre-specified secondary neonatal outcomes of
providing antenatal dietary and lifestyle advice to women who are overweight or obese.
Methods: We report a range of pre-specified secondary neonatal outcomes from a large randomised trial in which
antenatal dietary and lifestyle advice was provided to women who were overweight or obese. Pregnant women
were eligible for participation with a body mass index of 25 kg/m2 or over, and singleton gestation between 10+0
and 20+0 weeks. Outcome measures included gestational age at birth; Apgar score below 7 at 5 minutes of age;
need for resuscitation at birth; birth weight above 4.5 kg or below 2.5 kg; birth weight, length and head circumference
(and Z-scores); admission to the nursery; respiratory distress syndrome; and postnatal length of stay. Data relating to the
primary outcome (large for gestational age infants defined as birth weight above the 90th centile) and birth weight
above 4 kg have been reported previously. Analyses used intention-to-treat principles.
Results: In total, 2,142 infants were included in the analyses. Infants born to women following lifestyle advice were
significantly less likely to have birth weight above 4.5 kg (2.15% versus 3.69%; adjusted risk ratio (aRR) = 0.59; 95%
confidence interval (CI) 0.36 to 0.98; P = 0.04), or respiratory distress syndrome (1.22% versus 2.57%; aRR = 0.47; 95% CI
0.24 to 0.90; P = 0.02), particularly moderate or severe disease, and had a shorter length of postnatal hospital stay
(3.94 ± 7.26 days versus 4.41 ± 9.87 days; adjusted ratio of means 0.89; 95% CI 0.82 to 0.97; P = 0.006) compared with
infants born to women who received Standard Care.
Conclusions: For women who are overweight or obese, antenatal dietary and lifestyle advice has health benefits for
infants, without an increase in the risk of harm. Continued follow-up into childhood will be important to assess the
longer-term effects of a reduction in high infant birth weight on risk of child obesity.
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Globally, it is estimated that 170 million children under
the age of 18 years [1], are overweight or obese. Obesity
is occurring at an increasingly early age, affecting more
than 43 million children aged 0 to 5 years world-wide
[2], and 21% of Australian children 2 to 3 years of age
[3]. The World Health Organization has described child-
hood obesity as “one of the most serious public health
challenges of the 21st century”, [4] with obese children
exposed to its consequences, including disease progres-
sion and disability, earlier and for longer duration.
The economic costs of childhood obesity are profound
[5]. Australian data indicate that children who are over-
weight or obese at 5 years of age have medical costs
within the first 5 years of school that are $9.8 million
higher than those of children of normal body mass index
(BMI) [6]. Data from the USA indicate that childhood
overweight and obesity are associated with an additional
cost of $14.1 billion annually, reflecting prescription
drugs and emergency and outpatient attendances [7],
with a further $238 million annually reflecting inpatient
admissions [8]. The direct medical costs, in both child-
hood and adulthood, directly attributable to high child-
hood BMI have been conservatively estimated to be
$6.24 billion, with over 2 million quality adjusted life
years lost [5].
The intra-uterine environment is recognised as playing
a key role in the development of later health and disease
[9], representing a crucial period in the subsequent pro-
gramming of obesity. Both high maternal BMI and ex-
cessive gestational weight gain have been consistently
associated with adverse pregnancy outcomes [10-13], and
are significant predictors of increased adiposity and future
child/adult obesity [14-17], with some studies also finding
consequent associations with cardiometabolic risk factors,
including higher blood pressure [18,19]. The antenatal
period therefore represents a unique window in which
intervention designed to alter maternal diet and weight
gain may significantly influence infant adiposity, and mod-
ify future risk of both child and adulthood obesity.
Although there is considerable research focused on
the effects of dietary and lifestyle interventions to limit
gestational weight gain by pregnant women who are
overweight or obese, their effect on neonatal outcomeshas been poorly reported in the literature to date
[20-22]. In the few studies specifically involving women
who are overweight or obese where birth outcomes have
been reported, the predominant focus has been on infant
birth weight, with no reporting of other relevant clinical
infant outcomes [20-22]. We report the findings of the
LIMIT randomised trial, evaluating the provision of ante-
natal dietary and lifestyle advice to women who were over-
weight or obese on a range of pre-specified secondary
neonatal health outcomes.
Methods
Ethics
Ethics approval was granted by the Women’s and
Children’s Local Health Network Human Research and
Ethics Committee at the Women’s and Children’s Hospital,
the Central Northern Adelaide Health Service Ethics of
Human Research Committee (Lyell McEwin Hospital) and
the Flinders Clinical Research Ethics Committee (Flinders
Medical Centre). Approval to conduct the trial was pro-
vided by the Human Research and Ethics Committee at
each participating centre, and all participants provided
written informed consent.
Study design
We conducted a multicentre randomised trial across the
three major metropolitan maternity hospitals within
Adelaide, South Australia. The methods [23] and pri-
mary findings [24] of the LIMIT randomised trial have
been reported previously, and the trial has been regis-
tered on the Australian and New Zealand Clinical Trials
Registry (ACTRN12607000161426). Additional clinical
neonatal outcomes were added to the final working
protocol, reflecting piloting of data collection processes.
These amendments were pre-specified in the final work-
ing protocol, early in the conduct of the trial, and prior
to any analyses being undertaken.
Inclusion and exclusion criteria
Women with a BMI of 25 kg/m2 or greater and single-
ton pregnancy between 10+0 and 20+0 weeks gestation
were eligible to participate in the trial. Women with a
multiple pregnancy, or type 1 or 2 diabetes diagnosed
prior to pregnancy were ineligible.
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All women had their height and weight measured and
their BMI calculated at their first antenatal appointment,
and eligible women were counselled about participation.
Randomisation, masking and group allocation
Randomisation occurred by telephoning the central ran-
domisation service, using a computer-generated sched-
ule, with balanced variable blocks, and stratification for
parity (0 versus ≥1), BMI at antenatal booking (25 to
29.9 kg/m2 versus ≥30 kg/m2), and collaborating centre.
Women were randomised and allocated to either ‘Lifestyle
Advice’ or ‘Standard Care’.
Intervention
Lifestyle advice group
Women randomised to receive Lifestyle Advice partici-
pated in a comprehensive dietary and lifestyle intervention
over the course of their pregnancy, which included a com-
bination of dietary, exercise and behavioural strategies, de-
livered by a research dietician and trained research
assistants [23]. Women were provided with dietary ad-
vice consistent with current Australian standards [25];
to maintain a balance of carbohydrates, fat and pro-
tein, to reduce intake of foods high in refined carbohy-
drates and saturated fats, while increasing intake of
fibre, and to promote consumption of two servings
of fruit, five servings of vegetables, and three servings
of dairy each day [25]. Physical activity advice primar-
ily encouraged women to increase their amount of
walking and incidental activity [26]. The content and
structure of the intervention sessions has been described
in detail previously [24].
Standard care group
Women randomised to receive Standard Care continued
their pregnancy care according to local hospital guide-
lines, which did not include routine provision of advice
related to diet, exercise or gestational weight gain.
Study outcomes
In clinical practice, there is considerable variation in def-
initions of ‘large for gestational age’, including birth
weight at or above the 90th centile for gestational age
and infant sex, birth weight above 4 kg, and birth weight
above 4.5 kg, which are often used interchangeably.
These have been recognised as associated with early
childhood obesity [18,27], and were chosen as out-
come measures in the LIMIT randomised trial. The in-
cidence of infants born large for gestational age (birth
weight ≥90th centile for gestational age and infant sex;
primary outcome), and with birth weight above 4 kg have
been reported previously [24]. Pre-specified secondary
neonatal outcomes included gestational age at birth;Apgar score of 7 or above at 5 minutes of age; need for
resuscitation at birth; birth weight above 4.5 kg or below
2.5 kg; birth weight (and Z-scores); birth length (and
Z-scores); head circumference (and Z-scores); admis-
sion to neonatal intensive care unit; admission to spe-
cial care baby unit; respiratory distress syndrome [28]
(with moderate or severe disease defined as mean air-
way pressure >10 cm H2O and/or inspired oxygen fraction
(FiO2) >0.80 with ventilation); proven systemic infection
requiring treatment; retinopathy of prematurity; necrotis-
ing enterocolitis; neonatal encephalopathy [29]; seizures;
and postnatal length of stay.
Ponderal Index was calculated using birth weight and
length (kg/m3). Predicted fat free mass was calculated
using the following formula:
0:507þ 0:646 weight kgð Þ ‐0:089 sexþ 0:009
 length cmð Þ;
where 1 =male and 2 = female [30].
Analysis and reporting of results
Analyses were performed on an intention-to-treat basis,
according to the treatment group allocated at random-
isation. Multiple imputation was performed separately
by treatment group, using chained equations to create
100 complete datasets for analysis. Women who with-
drew consent to use their data, or had a miscarriage, ter-
mination of pregnancy, or stillbirth, were excluded from
the imputation and analysis. Sensitivity analyses were
performed using the available data and different imput-
ation models. Binary outcomes were analysed using log
binomial regression, with treatment effects expressed as
relative risk (RR), or Fisher’s exact test with no imput-
ation for rare outcomes. Continuous outcomes were
analysed using linear regression, with treatment effects
expressed as differences in means. Count outcomes were
analysed using Poisson regression, or using negative bi-
nomial regression where over-dispersion was present,
with treatment effects expressed as ratios of means.
Both unadjusted and adjusted analyses were per-
formed, with adjustment for the stratification variables.
Outcomes derived from birth weight were additionally
adjusted for maternal age, socioeconomic status and ma-
ternal smoking. Statistical significance was considered at
P < 0.05 (two-sided) with no adjustment for multiple
comparisons. All analyses followed a pre-specified statis-
tical analysis plan and were performed using SAS soft-
ware (v9.3; SAS Inc., Cary, NC, USA).
Sample size
Our predetermined sample size of 2,180 women was
based on our primary trial outcome, the incidence of
large for gestational age infants [24].
Figure 1 Flow of participants through the trial.
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Between June 2008 and December 2011, we recruited and
randomised 2,212 women, with 1,108 allocated to receive
Lifestyle Advice, and 1,104 Standard Care (Figure 1). There
was a total of 2,142 live-born infants included in the
analyses (1,075 Lifestyle Advice; 1,067 Standard Care). The
characteristics of women at the time of randomisation
were similar between treatment groups (Table 1).
There were no statistically significant differences identi-
fied between the two treatment groups with regards to
gestational age at birth (Lifestyle Advice 39.29 ± 1.74
weeks versus Standard Care 39.23 ± 2.07 weeks; adjusted
difference in means 0.07; 95% confidence interval (CI) 0.10
to 0.23; P = 0.42) (Table 2). However, infants born to
women allocated to Lifestyle Advice were less likely to
weigh above 4.5 kg (Lifestyle Advice 2.15% versus Standard
Care 3.69%; adjusted risk ratio (aRR) = 0.59; 95% CI 0.36 to
0.98; number needed to treat (NNT) = 66; 95% CI 34 to
950; P = 0.04), compared with infants born to women al-
located to Standard Care. This finding is consistent with
our previous report of a significant 18% RR reduction in
birth weight above 4 kg [24]. Furthermore, infants born
to women allocated to Lifestyle Advice were shorter
(birth length z-score −0,26 ± 0,76 versus −0,18 ± 0,80;
adjusted difference in means −0,07; 95% CI −0,14 to −0,01;
P = 0,04) than infants born to women allocated to Standard
Care.There was no statistically significant difference in infant
admission to neonatal intensive care (Lifestyle Advice
1.12% versus Standard Care 2.18%; aRR = 0.51; 95% CI 0.26
to 1.02; P = 0.06). However, infants born to women follow-
ing Lifestyle Advice were less likely to have respiratory
distress syndrome (Lifestyle Advice 1.22% versus Standard
Care 2.57%; aRR = 0.47; 95% CI 0.24 to 0.90; NNT= 75;
95% CI 40 to 532; P = 0.02), particularly moderate or severe
respiratory disease (Lifestyle Advice 0.09% versus Standard
Care 1.42%; P < 0.001), compared with infants born to
women allocated to Standard Care (Table 2). Infants born
to women in the Lifestyle Advice group also had a shorter
postnatal length of hospital stay (3.94 ± 7.26 days versus
4.41 ± 9.87 days; adjusted difference in means 0.89; 95% CI
0.82 to 0.97; P = 0.006). There were no other statistically
significant differences in infant outcomes identified be-
tween the groups.
Sensitivity analyses produced similar results, and did
not alter the conclusions regarding the effectiveness of
treatment in either the unadjusted or adjusted analysis for
any outcome (data not shown).
Discussion
Our findings indicate that provision of lifestyle advice to
women who are overweight or obese during pregnancy is
associated with a significant reduction in the risk of birth
weight above 4.5 kg, in addition to a significant reduction
Table 1 Demographic and clinical characteristics at trial entry (baseline)
Characteristic Lifestyle advice (n = 1105a) Standard care (n = 1097a) Total (n = 2202a)
Maternal age, yearsb 29.3 ± 5.4 29.6 ± 5.6 29.4 ± 5.5
Gestational age at entry, weeksc 14.0 (11.9 to 17.0) 14.1 (11.9 to 17.0) 14.1 (11.9 to 17.0)
Body mass index, kg/m2c 31.0 (28.1 to 35.9) 31.1 (27.7 to 35.6) 31.1 (27.9 to 35.8)
Body mass index categoryd
25.0 to 29.9 458 (41.4) 468 (42.7) 926 (42.1)
30.0 to 34.9 326 (29.5) 318 (29.0) 644 (29.2)
35.0 to 39.9 202 (18.3) 183 (16.7) 385 (17.5)
≥40.0 119 (10.8) 128 (11.7) 247 (11.2)
Public patientc 1081 (97.8) 1067 (97.3) 2148 (97.5)
Weight, kgb 88.6 ± 17.3 88.2 ± 17.6 88.4 ± 17.4
Height, cmb 164.9 ± 16.6 164.8 ± 16.5 164.8 ± 16.6
Racec
Caucasian 995 (90.0) 998 (91.0) 1993 (90.5)
Asian 26 (2.4) 34 (3.1) 60 (2.7)
Indian 40 (3.6) 35 (3.2) 75 (3.4)
Other 44 (4.0) 30 (2.7) 74 (3.4)
Smokerc 154 (13.9) 126 (11.5) 280 (12.7)
Nulliparousc 457 (41.4) 441 (40.2) 898 (40.8)
Previous preterm birthc 57 (5.2) 59 (5.4) 116 (5.3)
Previous pre-eclampsiac 46 (4.2) 51 (4.6) 97 (4.4)
Previous stillbirthc 13 (1.2) 6 (0.5) 19 (0.9)
Previous neonatal deathc 11 (1.0) 7 (0.6) 18 (0.8)
Previous caesarean sectionc 197 (17.8) 214 (19.5) 411 (18.7)
Family history of diabetesc 288 (26.1) 290 (26.4) 578 (26.2)
Family history of hypertensionc 389 (35.2) 369 (33.6) 758 (34.4)
Family history of heart diseasec 187 (16.9) 179 (16.3) 366 (16.6)
Index of socio-economic disadvantagee
Unknown 2 (0.2) 1 (0.1) 3 (0.1)
Quintile 1, (most disadvantaged) 340 (30.8) 321 (29.3) 661 (30.0)
Quintile 2 271 (24.5) 264 (24.1) 535 (24.3)
Quintile 3 173 (15.7) 174 (15.9) 347 (15.8)
Quintile 4 150 (13.6) 178 (16.2) 328 (14.9)
Quintile 5, (least disadvantaged) 169 (15.3) 159 (14.5) 328 (14.9)
aIncludes all women randomised who did not withdraw consent to use their data.
bMean ± standard deviation.
cMedian (interquartile range).
dn (%).
eSocioeconomic index as measured by SEIFA (socioeconomic indexes for areas [31]).
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ate or severe disease, and a shorter postnatal hospital length
of stay. Importantly, we did not identify any increase in the
risk of harm, including low infant birth weight.
Our randomised trial has a number of strengths, in-
cluding being the largest to date to evaluate the effect
on clinically relevant neonatal outcomes of an antenatal
lifestyle intervention for overweight or obese women. We
utilised robust methodology, including blinding of outcomeassessors and central randomisation, and achieved a high
rate of infant follow-up and available birth outcome data.
Our trial is not without limitations. As highlighted
previously [24], a potential limitation is the generalisability
of our findings, with 60% of eligible women declining to
participate (Figure 1). However, the demographic character-
istics of women participating in the LIMIT trial are similar
to the characteristics of the broader South Australian birth-
ing population [32], providing reassurance that our findings
Table 2 Infant outcomes by treatment group
Outcome Lifestyle advice
(n = 1075a)
Standard care
(n = 1067a)
Unadjusted Adjusted
Treatment effect
(95% CI)
P-value Treatment effect
(95% CI)
P-value
GA at birth, weeksb 39.29 ± 1.74 39.23 ± 2.07 0.06 (−0.10 to 0.23) 0.44 0.07 (−0.10 to 0.23) 0.42
Apgar score <7 at 5 minutes 22 (2.07) 22 (2.09) 0.99 (0.55 to 1.78) 0.98 0.99 (0.55 to 1.77) 0.97
Resuscitation required at birth 196 (18.23) 191 (17.89) 1.02 (0.85 to 1.22) 0.84 1.01 (0.85 to 1.21) 0.88
Birth weight, gb 3481 ± 554 3492 ± 613 −11.55 (−61.13 to 38.03) 0.65 −6.90 (−55.47 to 41.67) 0.78
Birth weight Z-scoreb 0.37 ± 1.03 0.43 ± 1.09 −0.06 (−0.15 to 0.03) 0.18 −0.05 (−0.14 to 0.03) 0.23
Birth length, cmb 49.84 ± 2.42 49.92 ± 2.84 −0.08 (−0.31 to 0.14) 0.48 −0.08 (−0.30 to 0.15) 0.51
Birth length Z-scoreb −0.26 ± 0.76 −0.18 ± 0.80 −0.07 (−0.14 to −0.01) 0.03 −0.07 (−0.14 to −0.01) 0.04
Birth head circumference, cmb 34.77 ± 1.60 34.77 ± 1.90 0.00 (−0.15 to 0.15) 0.96 0.01 (−0.14 to 0.16) 0.92
Birth head circumference Z-scoreb 0.21 ± 1.03 0.26 ± 1.09 −0.05 (−0.14 to 0.04) 0.31 −0.05 (−0.14 to 0.04) 0.32
Birth weight ≥4.5 kg 23 (2.15) 39 (3.69) 0.58 (0.35, 0.97) 0 · 04 0 · 59 (0 · 36, 0 · 98) 0 · 04
Birth weight ≤2.5 kg 43 (4.03) 56 (5.29) 0.76 (0.51 to 1.13) 0.18 0.74 (0.50 to 1.09) 0.13
Ponderal index, kg/m3b 27.95 ± 2.85 27.82 ± 2.91 0.12 (−0.12 to 0.37) 0.33 0.12 (−0.12 to 0.36) 0.34
Predicted fat free mass, kgb 3.07 ± 0.38 3.08 ± 0.42 −0.01 (−0.04 to 0.02) 0.59 −0.01 (−0.04 to 0.03) 0.73
Admission to NICU ≥4 days 12 (1.12) 23 (2.18) 0.52 (0.26 to 1.03) 0.06 0.51 (0.26 to 1.02) 0.06
Admission to SCBU 388 (36.12) 382 (35.77) 1.01 (0.90 to 1.13) 0.87 1.00 (0.90 to 1.12) 1.00
Respiratory distress syndrome 13 (1.22) 27 (2.57) 0.47 (0.25 to 0.91) 0.03 0.47 (0.24 to 0.90) 0.02
Respiratory support 65 (6.09) 77 (7.20) 0.84 (0.61 to 1.16) 0.30 0.84 (0.61 to 1.15) 0.27
Moderate/severe respiratory disease 1 (0.09) 15 (1.42) N/A <0.001d N/A N/A
Discharged home on oxygen 1 (0.09) 3 (0.28) N/A 0.37d N/A N/A
Patent ductus arteriosus 2 (0.19) 5 (0.47) N/A 0.29d N/A N/A
Proven systemic infection 0 (0.00) 2 (0.19) N/A 0.25d N/A N/A
Retinopathy of prematurity 1 (0.09) 4 (0.38) N/A 0.22d N/A N/A
Necrotising enterocolitis 3 (0.28) 1 (0.09) N/A 0.62d N/A N/A
Neonatal encephalopathy 0 (0.00) 0 (0.00) N/A N/A N/A N/A
Neonatal seizures 1 (0.09) 3 (0.28) N/A 0.37d N/A N/A
Postnatal length of stay infant, dayse 3.94 ± 7.26 4.41 ± 9.87 0.89 (0.82 to 0.97) 0.007 0.89 (0.82 to 0.97) 0.006
NICU, neonatal intensive care unit; SCBU, special care baby unit.
aIncludes all live-born infants.
bValues are mean ± SD, and treatment effects are differences in means based on imputed data.
cValues are n(%), and treatment effects are relative risks based on imputed data.
eValues are mean ± SD, and treatment effects are ratios of means based on imputed data.
dP-value derived Fisher’s exact test based on available data.
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to acknowledge that we report a number of secondary neo-
natal health outcomes. Although all were pre-specified, the
study was not powered to identify differences in many of
the secondary outcomes occurring relatively infrequently,
and interpretation should therefore be with an elem-
ent of caution.
The findings of a significant 41% RR reduction in birth
weight above 4.5 kg among infants born to women follow-
ing Lifestyle Advice compared with Standard Care is
consistent with the 18% RR reduction in birth weight above
4.0 kg reported previously [24]. Immediate birth conse-
quences associated with high infant birth weight are wellrecognised, and include shoulder dystocia and its sequelae,
perinatal asphyxia, neonatal hypoglycaemia, need for
nursery admission [33-36], and respiratory distress syn-
drome [37]. However, meta-analyses of population-based
cohort studies indicate a longer-term association between
high infant birth weight and an increased risk of both child
[38,39] and adulthood overweight and obesity [40,41].
Observational data from 7,738 14-year-old adolescents in
the United States Early Childhood Longitudinal Study [42]
highlighted a significantly higher prevalence of obesity
among children with birth weight above 4 kg. Whereas
children of high birth weight represented 12% of the
cohort, 36% of individuals who were obese at 14 years of
Dodd et al. BMC Medicine 2014, 12:163 Page 7 of 9
http://www.biomedcentral.com/1741-7015/12/163age had birth weights over 4 kg [42]. Antenatal interven-
tions that are successful in reducing the risk of high infant
birth weight therefore represent a public health strategy of
significant potential in tackling the increasing problem of
overweight and obesity, both in the short and longer term
[43,44]. The ongoing follow-up of infants born to women
who participated in the LIMIT trial is therefore of great im-
portance to evaluate the impact of reducing high infant
birth weight on subsequent early childhood obesity.
We observed a 53% RR reduction in neonatal respiratory
distress syndrome in infants born to women allocated the
lifestyle intervention. This difference in neonatal respiratory
distress syndrome was not explained by differences in the
use of antenatal corticosteroids, or in differences in
gestational age at birth. Some of this difference may reflect
the observed 26% reduction in preterm birth and the 53%
reduction in preterm pre-labour ruptured membranes
(PPROM) among women in the intervention group [24],
although these differences did not reach statistical
significance. Although some authors have identified an in-
creased risk of preterm birth in obese women [45], others
indicate that this reflects iatrogenic prematurity rather than
spontaneous labour [10]. In an analysis of the Danish
National Birth Cohort, Nohr and colleagues identified an
increased risk of preterm birth in obese women due to an
increase in PPROM, which was postulated to reflect an
increased risk of chorioamnionitis [46], although specific
description of neonatal respiratory morbidity was not pre-
sented. Although we observed a significant reduction in risk
of respiratory distress syndrome in infants born to women
allocated to the lifestyle intervention, our findings do not
suggest an aetiology related specifically to differences in risk
of PPROM, chorioamnionitis or infectious causes [24].
Increasingly, there is recognition that although the
consequences of preterm birth and prematurity can occur
in a setting of clinical chorioamnionitis, effects are also
evident following subclinical or histological inflammation
[47]. However, the pathways affected and precise mecha-
nisms remain to be determined, with evidence of an
imbalance in the production of pro-inflammatory and
anti-inflammatory cytokines [48]. There is increasing
recognition that adipose tissue is far from an inert storage
organ, being responsible for the active secretion of a num-
ber of metabolically active adipocytokines [49], and there
is a well-described association in non-pregnant individuals
between obesity and a low-grade inflammatory state
[50,51], which, while speculative, may share similarities
with subclinical chorioamnionitis.
Conclusions
To our knowledge, our findings are the first to describe a
significant reduction in neonatal respiratory morbidity
among infants born to women who are overweight or obese
following an antenatal dietary and lifestyle intervention.Furthermore, we postulate that this may be mediated by
the significant improvements in maternal diet and physical
activity following antenatal intervention, which we have
reported previously [52]. It will be important to further
consider specific dietary components and physical activity,
and the impact these factors may have on maternal
markers of inflammation, which are currently being evalu-
ated through our prospectively established bio-bank.
Evidence to date about the effect of antenatal dietary and
lifestyle interventions for women who are overweight or
obese has focused on gestational weight gain, to the detri-
ment of robust data describing both maternal and infant
health outcomes [53]. Our randomised trial addresses this
gap in the literature. Our findings indicate that providing
an antenatal dietary and lifestyle intervention for women
who are overweight or obese has health benefits for the
infant, without increasing the risk of harm. Continued
follow-up of participants, and ongoing interrogation of our
bio-bank will be important to identify potential mechanistic
pathways whereby changes to maternal diet and physical
activity impact on clinical outcomes.
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